KAMADA LTD. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 2,119 ILa | +1.05% |
|
+12.89% | -4.85% |
| Jul. 03 | Stifel Initiates Kamada at Buy With $18 Price Target | MT |
| May. 08 | Transcript : Kamada Ltd., Q1 2024 Earnings Call, May 08, 2024 |
ETFs positioned on Kamada Ltd.
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.04% | 0 M€ | 0.00% | - | |
| 0.01% | 0 M€ | 0.00% | - |
Kamada Ltd is Israel based company, focused on plasma-derived protein therapeutics with a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins.
Sector
Pharmaceuticals
Calendar
2024-08-13
- Q2 2024 Earnings Release (Projected)
Quarterly revenue - Rate of surprise
| 1st Jan change | Capi. | |
|---|---|---|
| -4.85% | 326M | |
| +4.18% | 97.7B | |
| +4.21% | 41.43B | |
| -11.86% | 32.85B | |
| +80.99% | 29.33B | |
| -14.25% | 15.47B | |
| -7.36% | 12.89B | |
| -13.08% | 11.51B | |
| +176.65% | 10.74B | |
| -57.36% | 8.97B |
- Stock Market
- Equities
- KMDA Stock
- ETFs Kamada Ltd.
